ANL Stock Summary and Trading Ideas (Adlai Nortye Group Ltd. - American Depositary Shares | NASDAQ:ANL)

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Adlai Nortye Group Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ANL.

As of August 21, 2026, ANL stock price declined to $13.70 with 102,162 million shares trading.

ANL has a beta of 3.26, meaning it tends to be more sensitive to market movements. ANL has a correlation of 0.05 to the broad based SPY ETF.

ANL has a market cap of $882.25 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that ANL belongs to (by Net Assets): CANC, BBC.

ANL has outperformed the market in the last year with a return of +720.4%, while the SPY ETF gained +21.2%. In the last 3 month period, ANL beat the market returning +20.6%, while SPY returned +3.6%. However, in the most recent 2 weeks ANL has underperformed the stock market by returning -1.0%, while SPY returned -0.4%.

ANL support price is $12.89 and resistance is $14.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANL shares will trade within this expected range on the day.